Loading
NASDAQHealthcareBiotechnology
Latest quote
$1.10
−$0.02 · -1.79%
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Regular session
$1.10
−$0.02 · -1.79%
Regular session · ET · Market data may be delayed.
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
52-week range
Current $1.10
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
47
Fair Value
Sentiment
33
Bearish
Risk
72
High Risk
Momentum
33
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
52-week range
Current $1.10
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 2.93M USD | 8.2M USD | 4.07M USD | 5.65M USD | 3.46M USD |
| Selling, general, and administrative | 4.84M USD | 4.31M USD | 3.97M USD | 4.02M USD | 4.4M USD |
| Operating expenses | 7.77M USD | 12.51M USD | 8.04M USD | 9.67M USD | 7.86M USD |
| Interest income | 215.04K USD | 225.78K USD | 247.22K USD | 63.57K USD | 45.61 USD |
| Interest expense | — | — | — | — | 45.61K USD |
| Depreciation and amortization | — | — | 8.04M USD | — | — |
| Operating income | −7.77M USD | −12.51M USD | −8.04M USD | −9.67M USD | −7.86M USD |
| Net income | −7.56M USD | −12.29M USD | −7.8M USD | −9.61M USD | −7.9M USD |
Company facts updated Oct 8, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 1, 2025 | 1:10 | — | — |
Stock split | May 16, 2024 | 1:15 | — | — |
Stock split | Mar 14, 2023 | 1:16 | — | — |
Effective Aug 1, 2025
1:10
Effective May 16, 2024
1:15
Effective Mar 14, 2023
1:16
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
